Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke

Mohammad Al-Tamimi, MD; Elizabeth E. Gardiner, PhD; Jim Y. Thom, M(App)Sc; Yang Shen, PhD; Matthew N. Cooper, BSc; Graeme J. Hankey, MD; Michael C. Berndt, PhD; Ross I. Baker, MBBS; Robert K. Andrews, PhD

**Background and Purpose**—Ischemic stroke induced by thrombosis may be triggered by atherosclerotic plaque rupture and collagen-induced platelet activation. Collagen induces glycoprotein VI shedding.

**Methods**—We measured plasma-soluble glycoprotein VI (sGPVI) by enzyme-linked immunosorbent assay in 159 patients with acute (<7-day) ischemic stroke and age/sex-matched community-based control subjects.

**Results**—sGPVI was elevated in stroke compared with controls (P=0.0168). ORs were higher in Quartile 4 for stroke cases (P=0.0121), and sGPVI was significantly elevated in stroke associated with large artery disease across Quartiles 2 to 4 and small artery disease in Quartile 4. sGPVI decreased 3 to 6 months after antiplatelet treatment, consistent with elevated sGPVI due to platelet activation during the thrombotic event. sGPVI correlated with P-selectin (P=0.0007) and was higher in individuals with the GPVIA haplotype (P=0.024).

**Conclusion**—Glycoprotein VI shedding is implicated in the pathology of acute ischemic stroke. (Stroke. 2011;42:00-00.)

**Key Words:** GPVI  ■  platelets  ■  stroke

The relative contribution of platelets to ischemic stroke varies between stroke etiologic subtypes, potentially modulating effectiveness of antiplatelet treatment.1-2 Atherosclerotic plaque rupture and platelet recruitment to exposed collagen triggers thrombotic stroke2 and the platelet-specific collagen receptor, glycoprotein VI (GPVI), initiates thrombus formation at arterial shear rates. Elevated platelet GPVI was reported in ischemic stroke,3 and GPVI inhibition provides protection in experimental stroke models.4 Collagen induces metalloproteinase-mediated shedding of GPVI, releasing plasma-soluble GPVI (sGPVI).5,6 We evaluated whether plasma sGPVI was a useful biomarker for stroke, how it compares with the platelet/endothelial activation marker P-selectin, and whether sGPVI is generated by acute stroke or is a general consequence of platelet activation in arterial disease. We also assessed whether sGPVI was correlated with GPVI Gln317/Leu polymorphisms.7

**Subjects and Methods**

The cohort of stroke patients and matched controls was collected with ethics approval (Royal Perth Hospital) and characterized for stroke/stroke subtypes.1-8 Plasma sGPVI was measured (blind) by enzyme-linked immunosorbent assay.9 The relationship between sGPVI and age/sex and Gln317 was assessed using multivariate linear regression using logged sGPVI to meet required regression assumptions. Age was centered to reduce multicollinearity. Association of sGPVI with stroke was assessed for paired cases/control subjects by multivariate logistic regression.

**Results**

Analysis of 159 stroke cases and 159 community-based control subjects matched for age/sex and postal code5,9 showed no significant correlation of sGPVI with age (mean, 67 years; range, 65 to 69 years) or sex (59 of 159 female) in either group. In the control group, standardized β coefficients (95% CI) were 0.013 (−0.11 to 0.14) for sex (P=0.836), and 0.0024 (−0.003 to 0.008) for age (P=0.368). In the stroke group, β values (95% CI) were −0.011 (−0.13 to 0.11) for sex (P=0.854) and 0.003 (−0.002 to 0.008) for age (P=0.297). There was an increase in plasma sGPVI between all stroke cases (21.5±9.1 ng/mL) compared with control subjects (19.7±8.1; P=0.0168). When analyzed by quartiles (Table 1), ORs were higher in Quartile 4 for stroke cases compared with control subjects. sGPVI was significantly elevated in large artery disease with a gradual, independent increase across Quartiles 2 to 4. sGPVI was increased in Quartile 4.
of small artery disease but not in cardioembolic stroke. In 59 of 159 available cases, 3 to 6 months after initial stroke, and treated with antiplatelet agents (aspirin), mean sGPVI (95% CI) decreased from 20.4 ng/mL (18.6 to 22.2) to 14.9 (13.5 to 16.3; paired t test P=0.003). The Pearson correlation coefficient for the linear relationship between sGPVI and P-selectin was 0.1899 (P=0.0007; Figure). GPVI polymorphism, Gln317 (Q/Q; GPVIa) compared with heterozygote (Q/L) and Leu317 (L/L; GPVIb), was not associated with stroke; however, elevated sGPVI significantly correlated with Gln317 (Table 2).

**Discussion**

Metalloproteinase-mediated shedding of human platelet GPVI potentially regulates GPVI-dependent platelet function during thrombus formation. Our study showing elevated sGPVI in patients with acute stroke at the time of the event, decreasing 3 to 6 months after antiplatelet treatment, provides the first evidence in humans that GPVI shedding is associated with atherothrombotic disease in vivo, consistent with a functional role for GPVI in experimental stroke models. GPVI shedding may decrease platelet reactivity to collagen. Dimeric sGPVI-Fc inhibits collagen binding/thrombus formation supporting a functional role for sGPVI, and a GPVI-Fc-based drug (Revacept) is in Phase I trials.

**Table 1. Association Between Plasma sGPVI and Stroke**

<table>
<thead>
<tr>
<th>Quartile</th>
<th>OR (95% CI)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (&lt;15.2 ng/mL)</td>
<td>1.61 (0.86–3.04)</td>
<td>0.1357</td>
</tr>
<tr>
<td>2 (15.2–18.7 ng/mL)</td>
<td>1.45 (0.80–2.67)</td>
<td>0.2267</td>
</tr>
<tr>
<td>3 (18.8–25.5 ng/mL)</td>
<td>2.25 (1.20–4.29)</td>
<td>0.0121</td>
</tr>
<tr>
<td>4 (&gt;25.5 ng/mL)</td>
<td>3.59 (1.26–11.25)</td>
<td>0.0020</td>
</tr>
</tbody>
</table>

*OR and 95% CIs compared with matched control subjects.†Reference Quartile 1; significance, P<0.05.

**Etiologic subtypes of acute ischemic stroke can be caused by thrombosis characterized by platelet activation related to atherosclerotic plaque rupture causing collagen exposure (“platelet-rich thrombus”) or cardioembolic stroke characterized by slow flow (stasis) associated with atrial fibrillation (“red cell-rich thrombus”). Our findings of increased sGPVI in large artery disease, and to a lesser extent small artery disease, but not cardioembolic stroke, might reflect the relative importance of platelets/platelet activation in stroke associated with vascular damage/collagen exposure and/or increased platelet GPVI expression. The correlation between sGPVI and P-selectin is consistent with activation-dependent shedding of GPVI leading to elevated sGPVI. Highest P-selectin levels are associated with Quartiles 1 to 3 rather than Quartile 4 of sGPVI, which could reflect increased endothelial-derived rather than platelet P-selectin, whereas GPVI is platelet-specific; E-selectin and von Willebrand factor are not increased in Quartile 4 (not shown).

Elevated sGPVI also correlated with the Gln317 polymorphism. GPVIa and b haplotypes involve 7 linked polymorphisms, 5 causing substitutions (Ser219Pro, Lys237Glu, Thr249Ala, Gln317Leu, His322Asn). Interestingly, Gln317Leu/His322Asn are proximal to a cytoplasmic calmodulin-binding site that regulates metalloproteinase-mediated shedding. Compared with GPVIa, GPVIb exhibits normal ligand binding but disrupted ligand-induced signaling. GPVIa shows lower-affinity calmodulin binding than GPVIb, which could increase susceptibility to shedding. Extracellular polymorphism Thr249Ala upstream of the cleavage site could also influence metalloproteinase-mediated shedding.

**Table 2. Association Between sGPVI and GPVI Genotype**

<table>
<thead>
<tr>
<th>Genotype</th>
<th>No. (%)</th>
<th>Mean sGPVI, ng/mL (Range)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln317</td>
<td>247 (70.4)</td>
<td>21.16 (20.01–22.31)</td>
<td></td>
</tr>
<tr>
<td>Heterozygote and Leu317</td>
<td>104 (29.6)</td>
<td>19.27 (17.36–21.17)</td>
<td>0.0241*</td>
</tr>
</tbody>
</table>

*P value compares heterozygote and Leu317 with Gln317. Significance, P<0.05.
Source of Funding
Supported by the National Health and Medical Research Council of Australia.

Disclosures
None.

References
Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke

Stroke. published online December 30, 2010;
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2010/12/30/STROKEAHA.110.602532

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/